The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun, 130021, Jilin, China.
J Exp Clin Cancer Res. 2019 Aug 14;38(1):354. doi: 10.1186/s13046-019-1359-9.
Estrogen receptor β (ERβ) has been reported to play an anti-cancer role in breast cancer, but the regulatory mechanism by which ERβ exerts this effect is not clear. Claudin-6 (CLDN6), a tight junction protein, acts as a tumor suppressor gene in breast cancer. Our previous studies have found that 17β-estradiol (E2) induces CLDN6 expression and inhibits MCF-7 cell migration and invasion, but the underlying molecular mechanisms are still unclear. In this study, we aimed to investigate the role of ERβ in this process and the regulatory mechanisms involved.
Polymerase chain reaction (PCR) and western blot were used to characterize the effect of E2 on the expression of CLDN6 in breast cancer cells. Chromatin immunoprecipitation (ChIP) assays were carried out to confirm the interaction between ERβ and CLDN6. Dual luciferase reporter assays were used to detect the regulatory role of ERβ on the promoter activity of CLDN6. Wound healing and Transwell assays were used to examine the migration and invasion of breast cancer cells. Western blot, immunofluorescence and transmission electron microscopy (TEM) were performed to detect autophagy. Xenograft mouse models were used to explore the regulatory effect of the CLDN6-beclin1 axis on breast cancer metastasis. Immunohistochemistry (IHC) was used to detect ERβ/CLDN6/beclin1 expression in breast cancer patient samples.
Here, E2 upregulated the expression of CLDN6, which was mediated by ERβ. ERβ regulated CLDN6 expression at the transcriptional level. ERβ inhibited the migration and invasion of breast cancer cells through CLDN6. Interestingly, this effect was associated with CLDN6-induced autophagy. CLDN6 positively regulated the expression of beclin1, which is a key regulator of autophagy. Beclin1 knockdown reversed CLDN6-induced autophagy and the inhibitory effect of CLDN6 on breast cancer metastasis. Moreover, ERβ and CLDN6 were positively correlated, and the expression of CLDN6 was positively correlated with beclin1 in breast cancer tissues.
Overall, this is the first study to demonstrate that the inhibitory effect of ERβ on the migration and invasion of breast cancer cells was mediated by CLDN6, which induced the beclin1-dependent autophagic cascade.
雌激素受体β(ERβ)已被报道在乳腺癌中发挥抗癌作用,但 ERβ 发挥这种作用的调节机制尚不清楚。紧密连接蛋白 Claudin-6(CLDN6)在乳腺癌中作为抑癌基因发挥作用。我们之前的研究发现,17β-雌二醇(E2)诱导 CLDN6 的表达并抑制 MCF-7 细胞的迁移和侵袭,但潜在的分子机制仍不清楚。在这项研究中,我们旨在研究 ERβ 在这一过程中的作用及其涉及的调节机制。
聚合酶链反应(PCR)和蛋白质印迹用于表征 E2 对乳腺癌细胞中 CLDN6 表达的影响。染色质免疫沉淀(ChIP)实验用于证实 ERβ 与 CLDN6 之间的相互作用。双荧光素酶报告基因实验用于检测 ERβ 对 CLDN6 启动子活性的调节作用。划痕愈合和 Transwell 实验用于检测乳腺癌细胞的迁移和侵袭。Western blot、免疫荧光和透射电子显微镜(TEM)用于检测自噬。异种移植小鼠模型用于研究 CLDN6-beclin1 轴对乳腺癌转移的调节作用。免疫组织化学(IHC)用于检测乳腺癌患者样本中 ERβ/CLDN6/beclin1 的表达。
在这里,E2 上调了 CLDN6 的表达,这是由 ERβ介导的。ERβ 在转录水平上调节 CLDN6 的表达。ERβ 通过 CLDN6 抑制乳腺癌细胞的迁移和侵袭。有趣的是,这种作用与 CLDN6 诱导的自噬有关。CLDN6 正向调节自噬的关键调节因子 beclin1 的表达。Beclin1 的敲低逆转了 CLDN6 诱导的自噬和 CLDN6 对乳腺癌转移的抑制作用。此外,ERβ 和 CLDN6 呈正相关,CLDN6 在乳腺癌组织中的表达与 beclin1 呈正相关。
总体而言,这是第一项研究表明,ERβ 对乳腺癌细胞迁移和侵袭的抑制作用是由 CLDN6 介导的,CLDN6 诱导了 beclin1 依赖性自噬级联反应。